153 related articles for article (PubMed ID: 37348162)
1. DNA methylation-based classifier differentiates intrahepatic pancreato-biliary tumours.
Dragomir MP; Calina TG; Perez E; Schallenberg S; Chen M; Albrecht T; Koch I; Wolkenstein P; Goeppert B; Roessler S; Calin GA; Sers C; Horst D; Roßner F; Capper D
EBioMedicine; 2023 Jul; 93():104657. PubMed ID: 37348162
[TBL] [Abstract][Full Text] [Related]
2. Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features.
Liau JY; Tsai JH; Yuan RH; Chang CN; Lee HJ; Jeng YM
Mod Pathol; 2014 Aug; 27(8):1163-73. PubMed ID: 24406866
[TBL] [Abstract][Full Text] [Related]
3. Molecular diagnosis of intrahepatic cholangiocarcinoma.
Haga H; Patel T
J Hepatobiliary Pancreat Sci; 2015 Feb; 22(2):114-23. PubMed ID: 25267595
[TBL] [Abstract][Full Text] [Related]
4. EMLI-ICC: an ensemble machine learning-based integration algorithm for metastasis prediction and risk stratification in intrahepatic cholangiocarcinoma.
Ruan J; Xu S; Chen R; Qu W; Li Q; Ye C; Wu W; Jiang Q; Yan F; Shen E; Chu Q; Jia Y; Zhang X; Fu W; Chen J; Timko MP; Zhao P; Fan L; Shen Y
Brief Bioinform; 2022 Nov; 23(6):. PubMed ID: 36259363
[TBL] [Abstract][Full Text] [Related]
5. Bile duct adenoma may be a precursor lesion of small duct type intrahepatic cholangiocarcinoma.
Sasaki M; Sato Y; Nakanuma Y
Histopathology; 2021 Jan; 78(2):310-320. PubMed ID: 33405289
[TBL] [Abstract][Full Text] [Related]
6. [Cholangiocarcinoma-diagnosis, classification, and molecular alterations].
Goeppert B
Pathologe; 2020 Sep; 41(5):488-494. PubMed ID: 32757029
[TBL] [Abstract][Full Text] [Related]
7. Differentiation of Intrahepatic Cholangiocarcinoma and Hepatic Lymphoma Based on Radiomics and Machine Learning in Contrast-Enhanced Computer Tomography.
Xu H; Zou X; Zhao Y; Zhang T; Tang Y; Zheng A; Zhou X; Ma X
Technol Cancer Res Treat; 2021; 20():15330338211039125. PubMed ID: 34499018
[No Abstract] [Full Text] [Related]
8. Methylation profiles of multiple CpG island loci in extrahepatic cholangiocarcinoma versus those of intrahepatic cholangiocarcinomas.
Kim BH; Cho NY; Choi M; Lee S; Jang JJ; Kang GH
Arch Pathol Lab Med; 2007 Jun; 131(6):923-30. PubMed ID: 17550320
[TBL] [Abstract][Full Text] [Related]
9. Albumin, filamin-A and cytokeratin 19 help distinguish intrahepatic cholangiocarcinoma from extrahepatic adenocarcinoma.
Chung YS; Jeon Y; Yoo JE; Chung T; Ryu HJ; Kim H; Rhee H; Park YN
Hepatol Int; 2023 Feb; 17(1):77-85. PubMed ID: 36253584
[TBL] [Abstract][Full Text] [Related]
10. DLEC1 methylation is associated with a better clinical outcome in patients with intrahepatic cholangiocarcinoma of the small duct subtype.
Kim Y; Lee K; Jeong S; Wen X; Cho NY; Kang GH
Virchows Arch; 2019 Jul; 475(1):49-58. PubMed ID: 30610381
[TBL] [Abstract][Full Text] [Related]
11. Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance.
Komuta M
Clin Mol Hepatol; 2022 Jul; 28(3):396-407. PubMed ID: 35032970
[TBL] [Abstract][Full Text] [Related]
12. Establishment and characterisation of six human biliary tract cancer cell lines.
Ku JL; Yoon KA; Kim IJ; Kim WH; Jang JY; Suh KS; Kim SW; Park YH; Hwang JH; Yoon YB; Park JG
Br J Cancer; 2002 Jul; 87(2):187-93. PubMed ID: 12107841
[TBL] [Abstract][Full Text] [Related]
13. [The role of molecular genetic factors in the development of cholangiocellular carcinoma].
Chulkova SV; Loginov VI; Podluzhnyi DV; Egorova AV; Syskova AY; Semichev DG; Gladilina IA; Kudashkin NE
Arkh Patol; 2022; 84(3):76-83. PubMed ID: 35639847
[TBL] [Abstract][Full Text] [Related]
14. Integrative Analysis Defines Distinct Prognostic Subgroups of Intrahepatic Cholangiocarcinoma.
Goeppert B; Toth R; Singer S; Albrecht T; Lipka DB; Lutsik P; Brocks D; Baehr M; Muecke O; Assenov Y; Gu L; Endris V; Stenzinger A; Mehrabi A; Schirmacher P; Plass C; Weichenhan D; Roessler S
Hepatology; 2019 May; 69(5):2091-2106. PubMed ID: 30615206
[TBL] [Abstract][Full Text] [Related]
15. Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma.
Yang B; House MG; Guo M; Herman JG; Clark DP
Mod Pathol; 2005 Mar; 18(3):412-20. PubMed ID: 15467712
[TBL] [Abstract][Full Text] [Related]
16. Feasibility of machine learning-based modeling and prediction using multiple centers data to assess intrahepatic cholangiocarcinoma outcomes.
Zhou SN; Jv DW; Meng XF; Zhang JJ; Liu C; Wu ZY; Hong N; Lu YY; Zhang N
Ann Med; 2023 Dec; 55(1):215-223. PubMed ID: 36576390
[TBL] [Abstract][Full Text] [Related]
17. An Expert, Multidisciplinary Perspective on Best Practices in Biomarker Testing in Intrahepatic Cholangiocarcinoma.
Madoff DC; Abi-Jaoudeh N; Braxton D; Goyal L; Jain D; Odisio BC; Salem R; Schattner M; Sheth R; Li D
Oncologist; 2022 Oct; 27(10):884-891. PubMed ID: 35925597
[TBL] [Abstract][Full Text] [Related]
18. Promoter methylation of INK4a/ARF as detected in bile-significance for the differential diagnosis in biliary disease.
Klump B; Hsieh CJ; Dette S; Holzmann K; Kiebetalich R; Jung M; Sinn U; Ortner M; Porschen R; Gregor M
Clin Cancer Res; 2003 May; 9(5):1773-8. PubMed ID: 12738733
[TBL] [Abstract][Full Text] [Related]
19. Role of epigenetic alterations in cholangiocarcinoma.
Tischoff I; Wittekind C; Tannapfel A
J Hepatobiliary Pancreat Surg; 2006; 13(4):274-9. PubMed ID: 16858537
[TBL] [Abstract][Full Text] [Related]
20. Anatomical, histomorphological and molecular classification of cholangiocarcinoma.
Kendall T; Verheij J; Gaudio E; Evert M; Guido M; Goeppert B; Carpino G
Liver Int; 2019 May; 39 Suppl 1():7-18. PubMed ID: 30882996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
